Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACHN is in the long-term down -79% below S&P in 6 years.
Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
|Shares Outstanding||EPS||-0.47||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-9|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.83%||ROE||-27.14%||ROI|
|Current Ratio||19.64||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.05|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||138.96 M||Cash From Investing Activities||-148.58 M||Cash From Operating Activities||-17.32 M||Gross Profit|
|Net Profit||-19.26 M||Operating Profit||-19.4 M||Total Assets||279.42 M||Total Current Assets||255.58 M|
|Total Current Liabilities||13.01 M||Total Debt||610 K||Total Liabilities||13.41 M||Total Revenue|
|High 52 week||5.15||Low 52 week||2.65||Last close||3.1||Last change||1.31%|
|RSI||20.21||Average true range||0.12||Beta||0.8||Volume||2.41 M|
|Simple moving average 20 days||-9.36%||Simple moving average 50 days||-12.63%||Simple moving average 200 days||-13.92%|
|Performance Week||-1.27%||Performance Month||-10.92%||Performance Quart||-26.37%||Performance Half||6.9%|
|Performance Year||-26.01%||Performance Year-to-date||7.64%||Volatility daily||2.03%||Volatility weekly||4.55%|
|Volatility monthly||9.32%||Volatility yearly||32.3%||Relative Volume||236.65%||Average Volume||1.22 M|
|New High||New Low|
2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4
2019-03-08 06:00:00 | Achillion to Present at the Barclays Global Healthcare Conference
2019-03-07 06:00:00 | Achillion Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-21 12:57:06 | Why a Connecticut pharma firm moved its C-suite to Blue Bell
2019-02-19 06:00:00 | Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
2019-02-12 07:50:00 | Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2019-02-11 06:00:00 | Achillion Appoints Brian Di Donato as Chief Financial Officer
2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up
2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
2019-01-10 10:49:30 | Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
2019-01-10 05:00:00 | Top Picks 2019- Achillian Pharmaceuticals ACHN
2019-01-03 06:00:00 | Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
2018-12-31 10:50:00 | 4 Healthcare Stocks That Are Raising Eyebrows
2018-12-20 16:30:00 | Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day
2018-12-19 15:45:00 | Why Achillion Pharmaceuticals Sank Again Today
2018-12-18 17:32:10 | Achillion Reports Positive Interim Data on Factor D Inhibitors
2018-12-18 16:33:00 | Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today
2018-12-18 15:02:00 | Why Achillion Pharmaceuticals Is Cratering Again Today
2018-12-17 16:33:00 | Why Achillion Pharmaceuticals Crashed Today
2018-12-16 14:18:20 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
2018-12-12 01:15:44 | Should You Buy Achillion Pharmaceuticals, Inc. ACHN?
2018-12-10 06:00:00 | Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
2018-12-08 18:19:51 | RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. ACHN: Is it Time To Buy?
2018-12-03 09:00:02 | Implied Volatility Surging for Achillion ACHN Stock Options
2018-11-07 06:30:01 | Achillion: 3Q Earnings Snapshot
2018-11-07 06:00:00 | Achillion Reports Third Quarter 2018 Financial Results
2018-10-18 13:14:42 | Does Achillion Pharmaceuticals Inc NASDAQ:ACHN Have A Volatile Share Price?
2018-10-17 07:40:00 | Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries — Discovering Underlying Factors of Influence
2018-09-25 06:00:00 | Achillion to Present at the Leerink Partners Roundtable Series
2018-09-14 09:09:01 | The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
2018-09-13 09:14:01 | IPOs and Foreign Investment Propel Biotech: 4 Top Picks
2018-09-10 06:00:00 | Achillion Appoints Paul Firuta Chief Operating Officer
2018-09-07 09:30:01 | Why Is Achillion ACHN Up 24.7% Since Last Earnings Report?
2018-08-31 04:14:08 | Achillion Pharmaceuticals ACHN Shares March Higher, Can It Continue?
2018-08-30 06:00:00 | Achillion to Present at the Baird 2018 Global Healthcare Conference
2018-08-23 11:39:13 | 7 Cheap Biotech Stocks to Buy Now
2018-08-08 19:30:43 | Achillion: 2Q Earnings Snapshot
2018-08-08 16:05:00 | Achillion Reports Second Quarter 2018 Financial Results
2018-07-17 08:14:27 | Achillion Pharmaceuticals: Analysts Are Mostly Positive in July
2018-07-11 11:05:03 | Achillion's 3rd Factor D Inhibitor Enters Clinical Studies